farletuzumab ecteribulin

DRUG5 trials

Sponsors

Bristol Myers Squibb International Corporation, Eisai Limited, Eisai Inc.

Conditions

Metastatic Non-Small Cell Lung CancerPlatinum-resistant High-grade Serous OvarianPrimary PeritonealSolid TumorSolid TumorsSolid tumors in 4 tumor types: platinum resistant ovarian cancerand non-small cell lung cancer adenocarcinoma; NSCLC).endometrial cancer (EC)

Phase 1

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

CompletedNCT03386942

Eisai Inc.Solid Tumors

Start: 2017-11-28End: 2022-10-26Updated: 2022-11-28

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

RecruitingNCT04300556

Eisai Inc.Solid Tumor

Start: 2020-08-06End: 2030-08-08Target: 182Updated: 2026-03-13

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types

Active, not recruitingCTIS2023-506868-14-00

Eisai Limitedand non-small cell lung cancer adenocarcinoma; NSCLC)., endometrial cancer (EC), Solid tumors in 4 tumor types: platinum resistant ovarian cancer +1

Start: 2023-02-28Target: 90Updated: 2025-12-29

Phase 2

A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, vs Investigator's Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

CompletedCTIS2023-504111-33-00

Bristol Myers Squibb International Corporationor Fallopian Tube Cancer, Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal

Start: 2023-02-14End: 2025-09-10Target: 55Updated: 2025-09-08

A Phase 2 Open-label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

CompletedCTIS2023-504112-15-00

Bristol Myers Squibb International CorporationMetastatic Non-Small Cell Lung Cancer

Start: 2023-01-04End: 2024-08-12Target: 25Updated: 2024-08-21

Related Papers

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results.

2025-12-23

Abstract CT056: A multicenter, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a folate-receptor-alpha-targeting antibody-drug conjugate in patients with selected tumor types

Cancer Research2023-04-14

4P Evaluation of antitumor activity and immunogenic cell death (ICD) induction by MORAb-202 (farletuzumab ecteribulin) in human ovarian cancer (OV) models

ESMO Open2023-02-011 citations

Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial.

Journal of Clinical Oncology2022-06-0114 citations

Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.

Journal of Clinical Oncology2022-06-012 citations

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Clinical Cancer Research2021-04-2990 citations

First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.

Journal of Clinical Oncology2019-05-207 citations